Shenzhen - Delayed Quote CNY
Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ)
15.90
-0.33
(-2.03%)
At close: 3:04:55 PM GMT+8
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Qun Liang | General Manager | -- | -- | 1971 |
| Mr. Ting Hao Yi | Financial Director | -- | -- | 1973 |
| Mr. Jian Gao | Board Secretary | -- | -- | 1977 |
| Mr. Zhenghua Huang | Deputy General Manager | -- | -- | 1972 |
Hubei Biocause Heilen Pharmaceutical Co., Ltd.
No. 122 Yangwan Road
Duodao District Jingmen High-tech Zone
Jingmen, 448000
China
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Description
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. The company provides APIs and intermediates, and formulations; and dimethyl ether gas and a-chloropropionyl chloride chemical products. It is also involved in the contract research, manufacture, and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc. The company was founded in 1995 and is based in Jingmen, China.
Corporate Governance
Hubei Biocause Heilen Pharmaceutical Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
May 27, 2024 at 12:00 AM UTC
Ex-Dividend Date